Advertisement

Heart and Vessels

, Volume 25, Issue 1, pp 19–26 | Cite as

A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine

  • Hasan Ari
  • Selma Ari
  • Ercan Erdoğan
  • Osman Tiryakioğlu
  • Yasemin Üstündağ
  • Kağan Huysal
  • Vedat Koca
  • Tahsin Bozat
Original Article

Abstract

The aim of this study is to investigate if serum asymmetric dimethylarginine (ADMA) levels can predict restenosis and major adverse cardiac events (MACE) in patients who undergo percutaneous coronary interventions. The most important cause of restenosis following percutaneous coronary intervention is neointimal hyperplasia. Nitric oxide (NO) prevents the neointimal hyperplasia growing. Asymmetric dimethylarginine is a competitive inhibitor of NO synthesis. The effect of ADMA on the restenosis has not yet been investigated. A total of 105 (80 male and 25 female) patients were included in our study. All patients underwent elective percutaneous transluminal coronary angioplasty (PTCA) with bare metal stent implantation or direct stenting for one coronary artery between September 2004 and January 2006. All patients were clinically followed for a period of 6 months, and a control angiography was performed at the end of this period. The probrain natriuretic peptide (pro-BNP), high-sensitivity Creactive protein (hs-CRP), and ADMA levels of the patients were evaluated before the procedure and 6 months afterwards. Biochemical parameters and angiographic features were evaluated in order to determine if they could predict the development of restenosis and MACE by using univariate and multivariate Cox regression analysis. The 65 (61.9%) patients (50 males and 15 females) who had not developed restenosis were designated as Group 1. The 27 (25.7%) patients (21 males and 6 females) who had developed restenosis were designated as Group 2. In terms of predicting the development of restenosis, the presence of diabetes mellitus (hazard ratio [HR]: 2.78; confidence interval [CI]: 1.25–6.20; P = 0.01), type of lesion (HR: 1.89; CI: 1.01–3.55; P = 0.04), form of procedure (HR: 0.30; CI: 0.11–0.81; P = 0.01), and ADMA (HR: 4.08; CI: 1.73–9.62; P = 0.001) were found to be significant in univariate Cox regression analysis. In contrast, only the levels of ADMA were found to be a significant predictor of restenosis in the multivariate Cox regression analysis (HR: 3.02; CI: 1.16–7.84; P = 0.02). The restenosis prediction of ADMA levels continued after excluding the patients with diabetes mellitus in the univariate and multivariate Cox regression analysis (HR: 5.23; CI: 1.99–13.76; P = 0.001 and HR: 5.61; CI: 1.79–17.62; P = 0.003, respectively). Regarding the development of cardiac events, hs-CRP (HR: 1.03; CI: 1.00–1.06; P = 0.01) and ADMA (HR: 17.1; CI: 3.06–95.8; P = 0.001) were found to be significantly correlated with adverse cardiac events in univariate Cox regression analysis, whereas only ADMA levels were significant in the multivariate Cox regression analysis (HR: 2.83; CI: 1.27–6.31; P = 0.01). The levels of ADMA obtained before the procedure predict the development of restenosis and MACE in patients who underwent elective PTCA and bare metal stent procedures.

Key words

Asymmetric dimethylarginine Restenosis Adverse cardiac event 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, Liao JK (1995) Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 96:60–682.CrossRefPubMedGoogle Scholar
  2. 2.
    Garg UC, Hassid A (1989) Nitric oxide-generating vasodilators and 8-bromo cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83:1774–1777CrossRefPubMedGoogle Scholar
  3. 3.
    Mooradian DL, Hutsell TC, Keefer LK (1995) Nitric oxide (NO) donor molecules: effect of NO release rates on vascular smooth muscle cell proliferation in vitro. J Cardiovasc Pharmacol 25: 674–678PubMedCrossRefGoogle Scholar
  4. 4.
    Tsao PS, Wang B, Buitrago R, Shyy JY, Cooke JP (1997). Nitric oxide regulates monocyte chemotactic protein-1. Circulation 96: 934–940PubMedGoogle Scholar
  5. 5.
    Tran CT, Leiper JM, Vallance P (2003) The DDAH/ADMA/NOS pathway. Atheroscler Suppl 4:33–40CrossRefPubMedGoogle Scholar
  6. 6.
    Azuma H, Sato J, Hamasaki H, Sugimoto A, Isotani E, Obayashi S (1995) Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells. Br J Pharmacol 115:1001–1004PubMedGoogle Scholar
  7. 7.
    Loscalzo J, Welch G (1995): Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 38:87–104CrossRefPubMedGoogle Scholar
  8. 8.
    Böger RH, Bode-Böger SM, Mügge A, Kienke S, Brandes R, Dwenger A, Frölich JC (1995). Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis 117:273–284CrossRefPubMedGoogle Scholar
  9. 9.
    Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S (1993) Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Lett 334:170–174CrossRefPubMedGoogle Scholar
  10. 10.
    Marks DS, Vita JA, Folts JD, Keaney JF Jr, Welch GN, Loscalzo J (1995) Inhibition of neointimal proliferation in rabbits following vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest 96:2630–2638CrossRefPubMedGoogle Scholar
  11. 11.
    Garg UC. Hassid A (1989) Nitric oxide generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83:1774–1777CrossRefPubMedGoogle Scholar
  12. 12.
    Rainer H. Böger (2003) The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 59:824–833CrossRefPubMedGoogle Scholar
  13. 13.
    Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J, Böger R (2001) Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). Lancet 358:2113–2117CrossRefPubMedGoogle Scholar
  14. 14.
    Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J, Laaksonen R (2001) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358:2127–2128CrossRefPubMedGoogle Scholar
  15. 15.
    Janero DR, Ewing JF (2000) Nitric oxide and postangioplasty restenosis: pathological correlates and therapeutic potential. Free Radic Biol Med 29:1199–1221CrossRefPubMedGoogle Scholar
  16. 16.
    Lu TM, Ding YA, Charng MJ, Lin SJ (2003) Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease. Clin Cardiol 26:458–464CrossRefPubMedGoogle Scholar
  17. 17.
    Wykretowicz A, Metzler L, Milewska A, Balinski M, Rutkowska A, Adamska K, Krauze T, Guzik P, Dziarmaga M, Wysocki H (2008) Noninvasively assessed pulsatility of ascending aortic pressure waveform is associated with the presence of coronary artery narrowing. Heart Vessels 23:16–19CrossRefPubMedGoogle Scholar
  18. 18.
    Lenzen H, Tsikas D, Böger RH (2006) Asymmetric dimethylarginine (ADMA) and the risk for coronary heart disease: the multicenter CARDIAC study. Eur J Clin Pharmacol 62:45–49CrossRefGoogle Scholar
  19. 19.
    Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Münzel T (2005) Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease. Circ Res 97:e53–e59CrossRefPubMedGoogle Scholar
  20. 20.
    Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR, März W (2007) Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health Study) Clin Chem 53:273–283CrossRefPubMedGoogle Scholar
  21. 21.
    Bae SW, Stühlinger MC, Yoo HS, Yu KH, Park HK, Choi BY, Lee YS, Pachinger O, Choi YH, Lee SH, Park JE (2005) Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol 95:729–733CrossRefPubMedGoogle Scholar
  22. 22.
    Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC (2003) Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 24:1912–1919CrossRefPubMedGoogle Scholar
  23. 23.
    Krempl TK, Maas R, Sydow K, Meinertz T, Böger RH, Kähler J (2005) Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J 26:1846–1851CrossRefPubMedGoogle Scholar
  24. 24.
    Fujita M, Nanto S, Oohara T, Morozumi T, Watanabe T, Nishio M, Awata M, Higo S, Oonishi T, Nagata S, Node K, Hori M, Kitakaze M (2002) Asymmetrical dimethyl arginine (ADMA) is a novel marker of coronary stent restenosis. Jpn Circ Soc Circ J 66suppl 1:41Google Scholar
  25. 25.
    Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, Tsujimoto T, Toyohira Y, Hayashida Y, Sasaguri Y, Ueta Y, Nakashima Y, Yanagihara N (2004) Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthasedeficient mice. Arterioscler Thromb Vasc Biol 24:1682–1688CrossRefPubMedGoogle Scholar
  26. 26.
    Tanaka M, Sydow K, Gunawan F, Jacobi J, Tsao PS, Robbins RC, Cooke JP (2005) dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 112:1549–1556CrossRefPubMedGoogle Scholar
  27. 27.
    Bogle RG, MacAllister RJ, Whitley GSJ, Vallance P (1995) Induction of NG-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases. Am J Physiol 269: C750–C756PubMedGoogle Scholar
  28. 28.
    Vallance P, Leiper J (2004) Cardiovascular biology of the asymmetric dimethylarginine: Dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 24:1023–1030CrossRefPubMedGoogle Scholar
  29. 29.
    Wojciak-Stothard B, Torondel B, Tsang LY, Fleming I, Fisslthaler B, Leiper JM, Vallance P. (2007) The ADMA/DDAH pathway is a critical regulator of endothelial cell motility. J Cell Sci 120: 929–942CrossRefPubMedGoogle Scholar
  30. 30.
    Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS (2002) Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287:1420–1426CrossRefPubMedGoogle Scholar
  31. 31.
    Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP (2002) Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106:987–992CrossRefPubMedGoogle Scholar
  32. 32.
    Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP, Reaven GM, Tsao PS (2002) Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 51:843–846CrossRefPubMedGoogle Scholar
  33. 33.
    Nash DT (2002) Insulin resistance, ADMA levels, and cardiovascular disease. JAMA 287:1451–1452CrossRefPubMedGoogle Scholar
  34. 34.
    Geng DF, Jin DM, Wu W, Wang Z, Wang JF (2008) Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: a meta-analysis of randomized controlled trials. Atherosclerosis 202:521–528CrossRefPubMedGoogle Scholar
  35. 35.
    Zairis MN, Ambrose JA, Manousakis SJ, Stefanidis AS, Papadaki OA, Bilianou HI, DeVoe MC, Fakiolas CN, Pissimissis EG, Olympios CD, Foussas SG; Global Evaluation of New Events and Restenosis After Stent Implantation Study Group (2002) The impact of plasma levels of C-reactive protein, lipoprotein (a), and homocysteine on the long-term prognosis after successful coronary stenting. J Am Coll Cardiol 40:1375–1382CrossRefPubMedGoogle Scholar
  36. 36.
    Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, Crea F, Maseri A (1999) Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 34:1512–1521CrossRefPubMedGoogle Scholar
  37. 37.
    Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schächinger V, Zeiher AM (2001) Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 37:839–846CrossRefPubMedGoogle Scholar
  38. 38.
    Hong YJ, Jeong MH, Lim SY, Lee SR, Kim KH, Sohn IS, Park HW, Kim JH, Kim W, Ahn Y, Cho JG, Park JC, Kang JC (2005) Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting. Circ J 69:1477–1483CrossRefPubMedGoogle Scholar
  39. 39.
    Lasave LI, Abizaid AA, Paiva e Maia J, de Ribamar Costa J Jr, Feres F, Mattos LA, Abizaid AS, Siqueira DA, Tanajura LF, Staico R, Beraldo de Andrade P, Braga SN, Sousa AG, Sousa JE (2007) Relationship between plasma C-reactive protein level and neointimal hyperplasia volume in patients with zotarolimus-eluting stents. Volumetric analysis by three-dimensional intracoronary ultrasound. Rev Esp Cardiol 60:923–931CrossRefPubMedGoogle Scholar
  40. 40.
    Ozer N, Tangurek B, Firat F, Ozer S, Tartan Z, Ozturk R, Ozay B, Ciloglu F, Yilmaz H, Cam N (2008) Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Heart Vessels 23:75–82CrossRefPubMedGoogle Scholar
  41. 41.
    Zairis MN, Ambrose JA, Manousakis SJ, Stefanidis AS, Papadaki OA, Bilianou HI, DeVoe MC, Fakiolas CN, Pissimissis EG, Olympios CD, Foussas SG (2002) The impact of plasma levels of c-reactive protein, lipoprotein (a) and homocysteine on the longterm prognosis after successful coronary stenting. J Am Coll Cardiol 40:1375–1382CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2010

Authors and Affiliations

  • Hasan Ari
    • 1
  • Selma Ari
    • 1
  • Ercan Erdoğan
    • 1
  • Osman Tiryakioğlu
    • 2
  • Yasemin Üstündağ
    • 3
  • Kağan Huysal
    • 4
  • Vedat Koca
    • 1
  • Tahsin Bozat
    • 1
  1. 1.Department of CardiologyBursa Postgraduate HospitalBursaTurkey
  2. 2.Department of Cardiac SurgeryBursa Postgraduate HospitalBursaTurkey
  3. 3.Department of BiochemistryBursa Şevket Yılmaz HospitalBursaTurkey
  4. 4.Department of BiochemistryBursa Postgraduate HospitalBursaTurkey

Personalised recommendations